Cargando…
Class 1 CF Mutations
Autor principal: | Wilschanski, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379685/ https://www.ncbi.nlm.nih.gov/pubmed/22723780 http://dx.doi.org/10.3389/fphar.2012.00117 |
Ejemplares similares
-
The effect of probiotic administration on metabolomics and glucose metabolism in CF patients
por: Gur, Michal, et al.
Publicado: (2022) -
Elucidating the Interaction of CF Airway Epithelial Cells and Rhinovirus: Using the Host-Pathogen Relationship to Identify Future Therapeutic Strategies
por: Ling, Kak-Ming, et al.
Publicado: (2018) -
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2022) -
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
por: Mainz, Jochen G., et al.
Publicado: (2023) -
Survey of CF mutations in the clinical laboratory
por: Huber, Klaus Roland, et al.
Publicado: (2002)